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PHOSPHO1, a newmember of the haloacid dehalogenase superfamily, has recently been implicated in the
mineralization process in both osteoblasts and chondrocytes. In this study we describe the identiﬁcation
of a novel, alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a). This transcript contains the three
exons of the previously published variant, however exon 3 contains a retained, 127 bp section of intron 2.
This forms an in-frame start site, producing an open reading frame of 879 bp and predicting a protein of
292 amino acids. The novel 40 amino acid N-terminal region of PHOSPHO1-3a contains a relatively strong
secretory signal, however all three domains of the HAD superfamily are retained in exon 3. The expres-
sion of this splice variant was conﬁrmed in both human and mouse osteoblast-like cells and also in the
chondrogenic ATDC5 cell line. The data within this study indicate a possible function relating to chondro-
cyte differentiation/mineralization as with the previously published variant.
 2008 Elsevier Inc. All rights reserved.PHOSPHO1 is a phosphatase enzyme belonging to the HAD
superfamily of hydrolases, which has been implicated in the gener-
ation of phosphate (Pi) for skeletal mineralization [1]. Initially
Phospho1 gene studies were done in the chicken (Gallus gallus),
however since then EST sequence database entries have been iden-
tiﬁed corresponding to human and murine Phospho1 which have
been subsequently ampliﬁed and cloned [2]. These transcripts have
a 94% identity to each other and are 62% identical to chick Phos-
pho1. The human and murine Phospho1 genes lying within approx-
imately 7.4 Kb regions on HSA17q21.32 and distal MMU11,
respectively, are ﬂanked by the ACLY and GH1 loci, and exhibit
conservation of synteny with part of GGA27. Using genetic linkage
analysis, chick Phospho1 was mapped to the syntenic region on
GGA27 [2]. This strongly suggests that the Phospho1 loci on
HSA17 and MMU11 are orthologous to the Phospho1 gene origi-
nally identiﬁed in the chick. Phospho1 has since been identiﬁed
in a number of species including rat, zebraﬁsh, and puffer ﬁsh
through EST analysis [3].
PHOSPHO1 has been shown to have a high speciﬁc phosphohy-
drolase activity toward phosphoethanolamine (PEA) and phospho-
choline (PCho) substrates [4]. PEA and PCho are involved in the
biosynthesis of phosphatidylethanolamine and phosphatidylcho-
line, respectively, and form the polar headgroups of phospholipids
in biological membranes. Both PEA and PCho levels are controlled
in vivo by the expression of CTP-dependent cytidyltransferases,ll rights reserved.
(C. Farquharson).which catalyze the formation of CDP-ethanolamine and CDP-cho-
line, respectively [5,6].
Phospho1 is expressed at high levels in bone tissue when com-
pared with non-skeletal tissues in both chick and murine models
[7,8]. Immunolocalization studies have shown that PHOSPHO1 is
speciﬁcally localized to mineralizing regions of skeletal tissue in
both species [8,9]. In addition to the protein localization studies,
Phospho1 transcript has also been localized in developing embry-
onic bones of the chick by in situ hybridization [1]. In this study
the transcript of Phospho1 has been found to be expressed at sites
destined for mineralization. Interestingly the transcript is present
at these sites prior to overt signs of mineralization thereby provid-
ing support to the suggestion that PHOSPHO1 is involved in the ini-
tial stages of mineralization.
This expression/localization pattern suggests PHOSPHO1 is clo-
sely associated with the mineralization process and in particular
the generation of Pi for hydroxyapatite production. This is an
essential phase of mineral formation, not only for the precipitation
with calcium but also to initially raise the Pi/PPi ratio to a degree
that is permissive to mineralization. This is due to PPi acting as a
powerful inhibitor of HA formation [10,11]. In addition, reduction
of PHOSPHO1 activity through the use of newly discovered small
molecule inhibitors causes a decrease in the capacity of MVs to cal-
cify in vitro. These data indicate that PHOSPHO1 has a role in the
mineralization process which is likely to be in the production of
Pi for calcium phosphate precipitation.
In this study we now describe the discovery of a novel Phospho1
transcript which is expressed in human osteoblasts. In addition, we
present data to suggest that both transcripts exist in murine oste-
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mineralization of these skeletal cells.Materials and methods
PCR ampliﬁcation of Phospho1 variants. Total RNA was isolated
from SaOS-2 human osteoblast-like cells by phenol/chloroform
extraction and treated with DNase I (Ambion) according to the
manufacturer’s instructions. The RT-PCR was carried out using
the SUPERSCRIPT—First Strand synthesis system for RT-PCR with
Oligo dT (Roche). Primer pairs for b-Actin RNA were used as a con-
trol. The reaction mixture contained 5 lg RNA, 500 ng Oligo dT, 2 ll
10 RT buffer, 2 mM MgCl2, 10 mM DTT, 0.5 mM DNTP’s, and
200 ll Superscript enzyme. The reaction was then cycled as fol-
lows: 25 C for 10 min, 42 C for 50 min, and 70 C for 15 min.
PCR primers (Exon1F 50-CCCCCTTCCCCACTTCTTAC-30, Exon1-2-
3aR 50-CCGGGAGAGGCTGGTTAG-30; amplicon size 230 bp and
Exon1F2 50-TACCTCAGCTAGCCCCCTTC-30, Exon1-2-3bR 50-CGGA
GATGAGAATCACCTCG-30; amplicon size 638 bp and 511 bp for
Phospho1-3a and the previously published isoform, respectively)
were designed to allow ampliﬁcation of exons created through
alternative splice patterns (deﬁned by EST analysis). Each tran-
script was ampliﬁed utilizing a 55 C annealing temperature and
200 ng cDNA. The PCR products were then electrophoresed on a
2% agarose gel and puriﬁed using the Qiagen QiaQuick gel extrac-
tion kit. The PCR products were cloned directly into the pGEM-T-
Easy vector. This plasmid is prelinearized and can ligate to the
deoxyadenosine (A) at the 30 ends of PCR products. The PCR prod-
uct and plasmid were ligated in a 3:1 ratio using 100 ng of PCR
product. This mixture was used to transform JM109 competent
cells. Liquid cultures and plasmid minipreparations of individual
clones were subsequently carried out. DNA sequencing of plasmids
was carried out by the DNA sequencing facility at Dundee
University.
Cell culture. The ATDC5 chondrocyte cell line was obtained from
the RIKEN cell bank (Ibaraki, Japan), and cells cultured at a density
of 6000 cells/cm2 in differentiation medium (DMEM:F12 (Invitro-
gen, Paisley, UK), 5% FCS (Invitrogen), 3  108 M sodium selenite,
10 lg/ml human transferrin (Sigma, Poole, UK), and 10 lg/ml insu-
lin (Sigma)). Cells were differentiated at 37 C in a humidiﬁed
atmosphere containing 5% CO2 for up to 15 days. We and others
have previously shown that from 8 days of differentiation, ATDC5
cells express the chondrocyte marker gene collagen type II, and
by day 15, the cells display a terminally differentiating phenotype,
with increased levels of collagen type X and aggrecan expression,
and the formation of nodules [12,13]. Some cultures were further
differentiated for 28 days to induce mineralization in the presence
of 10 mM b-glycerol phosphate (bGP) and 50 lg/ml ascorbate-2-
phosphate.
Mouse calvarial cells (wild-type Ob) were isolated from 3-day-
old mice through sequential collagenase digestion. Calvarial cells
were plated at a density of 20,000/cm2 in alpha-MEM (Gibco, Pais-
ley, UK) containing 10% FBS. MLO-A5 [14] cells were obtained from
L.F. Bonewald (University of Missouri, Kansas City, MO) and cul-
tured in a similar manner but seeded at 10,000/cm2.
PCR of genes during ATDC5 differentiation. RNAwas extracted and
reverse transcribed as described above. Primers for 18s RNA were
purchased from Applied Biosystems (Warrington, UK). Other prim-
ers were designed using the software program Primer3 (Whitehead
Institute for Biomedical Research); Phospho1: forward 50-GAC
AATGAGCGGGTGTTTTC-30, reverse 50-GGGGATGGTCTCGTAGACA
G-30; Aggrecan: forward 50-CGAGAATGACACCTGCTAGG-30 reverse
50-AAGAAGACAGGACCAGGAAGG-30, Collagen II (Coll2a): forward
50-GCCAAGACCTGAAACTCTGC-30 reverse 50-GGTTGGGGTAGACGCA
AGTC-30. The PCR mixture contained; 0.2 mM dNTP mix (Promega),5 ll of 10 PCR buffer (Roche), 5 units Taq polymerase (Roche),
0.5 lM of the forward and reverse primers, and 1 ll cDNA. This
was then cycled at: 94 C for 5 min, thirty cycles of 94 C for 30 s,
55 C for 30 s, and 72 C for 1 min, and ﬁnally one step on 72 C
for 10 min. Each reaction was analyzed on 1.5% agarose gels run
in the presence of ethidium bromide (250 lg/l).
Western blotting. Cell extracts were analyzed for the presence of
PHOSPHO1 by immunoblotting. Cell preparations were lysed in
PBS containing 1.6 mg/ml of Complete protease inhibitor cocktail
(Roche, Lewes, UK). Samples corresponding to 50 lg total protein
were incubated at 70 C for 10 min in LDS sample buffer before
loading. Samples were run on a 10% Bis–Tris NuPAGE gel and elec-
troblotted to nitrocellulose, which was incubated in blocking
solution (5% non-fat milk in Tris-buffered saline with 0.1% Tween
20). The membranes were then probed with a 1:750 dilution of
rabbit-anti-PHOSPHO1 antisera in blocking solution and washed
three times with PBS. Blots were then incubated with goat anti-
rabbit IgG-peroxidase (DAKO) diluted 1:2000 in blocking solution.
The immune complexes were then visualized by enhanced
chemiluminescence.Results
Identiﬁcation of a novel splice variant of Phospho1
We have previously reported the high expression of Phospho1 in
both mineralizing growth plate chondrocytes and osteoblasts from
murine sources. During these previous studies [8] a doublet band
was observed upon ampliﬁcation of Phospho1 between exons 2
and 3, and we have previously postulated that this was an alterna-
tive transcript from the Phospho1 gene. The presence of this dou-
blet was conﬁrmed in both primary osteoblasts and MLO-A5 cells
in this present study (Fig. 1A). A search of ESTs from the human
NCBI database revealed a sequence assigned BC029931 that per-
haps reinforced this hypothesis. This sequence from the Phospho1
gene had a section of retained intron from intron 2 (Fig. 2). In order
to investigate the possibility of an alternative splice variant, prim-
ers were designed to amplify a product containing exon 1–3. Prim-
ers were designed to simultaneously amplify both the variant
containing the novel exon—termed exon 3a and the original iso-
form. The ampliﬁcation products were cloned and sequenced. As
seen in Fig. 1B both splice variants can be ampliﬁed from SaOS-2
osteosarcoma cDNA, each identical apart from a 127 bp exon found
at the 50 region of exon 3 (Fig. 2B). The novel transcript can be
ampliﬁed both independently (Fig. 2B, lane 2) and along with the
previously published transcript (Fig. 2B, lane 3), depending on
the position of the reverse primer. This novel variant is termed
Phospho1-3a. This novel exon causes a frame shift, which in turn
causes the initiation site from exon 2 to be lost and a novel start
site to be created in exon 3a. Consequently, an open reading frame
of 879 nucleotides is formed, which can be translated into a protein
of 292 amino acids. All three motifs which form the conserved ac-
tive site from the HAD superfamily are conserved between both
splice variants as they are all located within exon 3.
Expression of Phospho1-3a in differentiating chondrocytes
The Phospho1 splice variants were ampliﬁed using primers
which crossed intron 2 and exon 3a of the Phospho1 gene, in order
that both variants would be ampliﬁed together. As can be seen in
Fig. 3A, the ATDC5 cell line progresses from a proliferating pheno-
type at day 0 to a terminally differentiated phenotype with the
presence of cartilaginous nodules (as indicated by arrows) at day
15. Both splice variants are identiﬁed in the differentiating cells
with apparent equal intensity, however there is an increase in both
Fig. 2. Structure of a novel alternatively spliced exon 3a. (A) Schematic representation of exon organization and protein domains in the Phospho1 splice variant. Arrows
indicate alternative ATG start sites. Note the presence of exon 3a does not affect any of the HAD conserved domains located in exon 3. (B) Phospho1-3a retains a 127 bp portion
of intron 2 (corresponding to nucleotides 44,657,239–44,657,366 of human chromosome 17) as a novel exon, termed exon 3a. Consensus sequence for RNA splicing acceptor
site; # consensus sequence for RNA splicing donor site.
Fig. 1. PCR products corresponding to splice variants of human Phospho1. (A) Ampliﬁcation of Phospho1 from exon 2 to exon 3 in wild-type murine osteoblasts (Ob) and pre-
osteocytes (MLO-A5) and (B) ampliﬁcation from exon 2 to exon 3a (lane 2) and exon 3 (lane 3) in human SaOS-2 cells. RNA was extracted from each cell type and reverse
transcribed before being ampliﬁed using gene speciﬁc primers as described in ‘‘Materials and methods”.
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(Fig. 3B). The differentiation of the chondrocytes is conﬁrmed by
the increase in expression of Aggrecan during the differentiation
process. The presence of Collagen II (Coll2a) transcript veriﬁes the
chondrocyte-like phenotype of the cells.
PHOSPHO1 protein levels in differentiating cells
To analyze the effect of differentiating factors on the presence of
PHOSPHO1 within mineralizing ATDC5 cells, the cells were
cultured in the presence of 10 mM bGP and 50 lg/ml ascorbate-
2-phosphate. Two forms of PHOSPHO1 (32 and 29 kDa) were
detected in each cell type corresponding to two splice variants
from the Phospho1 gene, as seen in Fig. 3C. However, PHOSPHO1
appeared to be constitutively expressed and protein levels did
not alter during the latter phase of matrix mineralization. Mineral-
ization was evident by day 22 (data not shown).
Discussion
In this study, we identiﬁed a novel splice variant from the Phos-
pho1 gene, named Phospho1-3a. The analysis of this splice variantreveals a protein with an alternative N-terminal region (Fig. 4),
termed exon 3a. This exon is formed from a retained 127 bp section
of intron 2, leading to the formation of a new in-frame ATG initia-
tion site giving rise to a novel 334 bp ORF.
This is not uncommon within the haloacid dehalogenase super-
family, in fact H+-K+-ATPases show a somewhat similar splicing pat-
tern with alternative transcriptional initiation and mRNA splicing
giving rise to distinct N-terminal variants of the HKalpha2 subunit
[15]. The splice variant of Phospho1 only differs in the N-terminal re-
gion, thus these variants are perhaps encoding PHOSPHO1 proteins
with slightly different functions within or outside the cell. Interest-
ingly, analysis of the 3a sequences with the program SignalP v3.0
[16] suggests the presence of a relatively strong secretory domain
hinting that this form is either being secreted or signaled to alterna-
tive sites within the cell (data not shown). All three domains within
the Phospho1 gene are conservedwithin exon 3b (Fig. 2A), indicating
that these splice variants are functioning against a common sub-
strate or substrate structure, as is seen in H+-K+-ATPases, where N-
terminal alteration causes a difference in pharmacological proﬁle
but not in substrate speciﬁcity. The splicing of pre-mRNA is tightly
controlled by spliceosomes following gene transcription but before
translation. These spliceosomes recognize the boundary found be-
Fig. 3. The effect of chondrocyte differentiation on Phospho1 expression. (A) The chondrogenic ATDC5 cells display phenotypic changes when differentiated in the presence of
sodium selenite, transferrin, and insulin, depicted by the presence of cartilaginous nodules (indicated by arrows) at day 15 of culture. (B) Expression of Phospho1, Aggrecan,
and Coll2a in ATDC5 cells during differentiation. Differentiation was conﬁrmed by the increase in aggrecan expression. RNA was extracted from each cell type and reverse
transcribed before being ampliﬁed using gene speciﬁc primers as described in Materials and methods. (C) Immunoblot examining PHOSPHO1 expression in protein isolated
from ATDC5 cells induced to mineralize. The cells were cultured in the presence of 10 mM bGP and 50 lg/ml ascorbate-2-phosphate. Mineralization of the monolayer was
evident by day 22.
Fig. 4. Comparison of amino acid alignment of human regular PHOSPHO1 and PHOSPHO1-3a. The predicted amino acid sequence of PHOSPHO1-3a is aligned with the amino
acid sequence of human PHOSPHO1. Note the identical sequence outwith the N-terminal region.
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out of intronic sequence and the joining of exons. The recognition
of speciﬁc splice sites relies on the presence of conserved intronic
di-nucleotides at the 50 (donor) and 30 (acceptor) exon–intron
boundaries.However further sequencesaround thesplice site are re-
quired for proper splicing [17].PHOSPHO1 has been shown to be involved in the mineralization
process through the production of Pi for hydroxyapatite crystal for-
mation. Its expression is restricted to cells of the skeleton where it
has been shown to be highly expressed by both mineralizing chon-
drocytes and osteoblasts [7–9]. Within the epiphyseal growth
plate, PHOSPHO1 protein has been located to prehypertrophic
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regions [8,9]. This observation suggests that PHOSPHO1 has a role
in the early stages of matrix mineralization. To analyze whether
Phospho1-3a is differentially expressed during these stages the
murine chondrogenic ATDC5 cell line was induced to differentiate
from a proliferating to a terminally differentiated phenotype. Both
Phospho1 transcripts were identiﬁed during this process at an
apparent equal expression; however a modest increase in expres-
sion levels was noted over time, which is in agreement with Chen
et al. (2005) [18]. This is similar to another haloacid dehalogenase-
like enzyme, Sarco/endoplasmic reticulum-type calcium transport
ATPase 2, where a novel splice variant was identiﬁed to be involved
in monocyte differentiation [19]. This splice variant, which is
formed in a similar fashion to Phospho1-3a—through an inclusion
of a small section of intronic sequence at the 30 region of the tran-
script, is upregulated during differentiation. As with PHOSHO1-3a
the novel variant of SERCA2 is modulated in a similar fashion to the
major isoform. This suggests that the novel splice variant from the
Phospho1 gene may be involved in chondrogenic differentiation
from a proliferating to hypertrophic phenotype along with the pre-
viously published isoform.
As Phospho1 has been implicated in the mineralization process,
ATDC5 cells were induced to mineralize through the addition of
bGP and ascorbate-2-phosphate for a period of 28 days. However,
upon analysis of PHOSPHO1 protein levels directly pre- and pro-
ceeding (detectable) matrix mineralization, the transcripts appear
to be constitutively expressed, although the larger, novel Phos-
pho1-3a is expressed at a higher level than the previously pub-
lished variant, suggesting a possible synergy between the two
isoforms. Similarly, the HAD enzyme epoxide hydrolase-2 has
three published isoforms which differ in their N-terminal regions
only [20,21]. All three isoforms are closely linked to the ovulation
process, however exact functions for these variants have yet to be
identiﬁed. It is therefore possible that this is also the case with
variants of Phospho1 and the mineralization process.
Phospho1 expression has been documented in alternative tis-
sues such as heart and bone marrow, although at considerably low-
er levels [8]. The identiﬁcation of the splice variant Phospho1-3a
may suggest alternative functions in tissues other than bone. Inter-
estingly, PHOSPHO1 has also been shown to be able to cleave PCho,
the hydrolysis of which has been studied in hamster heart and has
been shown to be catalyzed by an unidentiﬁed enzyme [22].
Recently PHOSPHO1 has been directly implicated in phase one
of matrix vesicle mineralization [8]. This process involves the in-
tra-vesicular formation of hydroxyapatite crystal and is critical
for normal bone growth and maintenance. The identiﬁcation of a
novel splice variant from this gene may serve to provide further in-
sights into this process or perhaps provide a means for Pi or PEA/
Cho production in distinct sites. However, elucidation of the pre-
cise function and location of Phospho1-3a would ﬁrst need to be
established.
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